Suppr超能文献

修订版电子RUCAM在中国患者药物性肝损伤诊断中的验证

Validation of the revised electronic version of RUCAM for diagnosis of DILI in Chinese patients.

作者信息

Zhao Xinyan, Wang Yan, Lai Rongtao, Wang Xiaojin, Yu Yuecheng, Li Min, Zhao Hong, Ma Zikun, Li Mengqi, Guo Tiantian, Han Xiao, Meng Yao, Zhang Mengmeng, Su Yu, Hao Kunyan, Deng You, Kong Yuanyuan, Li Zhenyu, Xie Qing, Xie Wen, Chen Chengwei, Jia Jidong

机构信息

Liver Research Center, Beijing Friendship Hospital, Capital Medical University; Key Laboratory on Translational Medicine on Cirrhosis; National Clinical Research Center for Digestive Diseases, Beijing, China.

Department of Infectious Diseases, Ruijing Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

出版信息

Hepatol Commun. 2024 Mar 11;8(4). doi: 10.1097/HC9.0000000000000235. eCollection 2024 Apr 1.

Abstract

BACKGROUND AIMS

The Revised Electronic Causality Assessment Method (RECAM), a computerized update of the Roussel Uclaf Causality Assessment Methodology (RUCAM), was recently proposed. In this study, we validated and compared the utility of the RECAM and RUCAM in Chinese patients with a single conventional or herbal agent-induced liver injury.

METHODS

In this retrospective multicenter cohort of well-established DILI and non-DILI patients from 5 centers in China, the diagnostic performance of the RUCAM and RECAM was compared by AUC analysis. The consistency was evaluated by weighted kappa. The major causes of discrepancy were explored.

RESULTS

A total of 481 DILI and 100 non-DILI patients were included. In total, 62.6% of the DILI cases were induced by conventional agents, and 37.4% were induced by herbs. The RECAM had relatively higher AUC than RUCAM for overall [0.947 (0.926-0.964) vs. 0.867 (0.836-0.893), p=0.0016], conventional agents [0.923 (0.890-0.949) vs. 0.819 (0.775-0.858), p=0.0185], and herbs [0.972 (0.941-0.989) vs.0.911 (0.866-0.944), p=0.0199]. Latency, scores associated with hepatitis B, and hepatotoxicity information of the insulting drugs were the 3 main causes for the inconsistency between RECAM and RUCAM scores.

CONCLUSIONS

The RECAM had relatively better diagnostic performance than RUCAM, with a higher AUC for Chinese DILI patients. Timely updates of the LiverTox category and refinement of serum markers to exclude hepatitis B activity would further improve the applicability of RECAM in areas where the use of herbs and resolution of past HBV infections are common.

摘要

背景与目的

修订后的电子因果关系评估方法(RECAM)是罗塞尔·优克福因果关系评估方法(RUCAM)的计算机化更新版本,最近被提出。在本研究中,我们验证并比较了RECAM和RUCAM在中国单一常规药物或草药引起肝损伤患者中的效用。

方法

在这项来自中国5个中心的已确诊药物性肝损伤(DILI)和非DILI患者的回顾性多中心队列研究中,通过AUC分析比较了RUCAM和RECAM的诊断性能。通过加权kappa评估一致性。探讨了差异的主要原因。

结果

共纳入481例DILI患者和100例非DILI患者。总体而言,62.6%的DILI病例由常规药物引起,37.4%由草药引起。RECAM在总体诊断方面的AUC相对高于RUCAM [0.947(0.926 - 0.964)对0.867(0.836 - 0.893),p = 0.0016],常规药物方面[0.923(0.890 - 0.949)对0.819(0.775 - 0.858),p = 0.0185],以及草药方面[0.972(0.941 - 0.989)对0.911(0.866 - 0.944),p = 0.0199]。潜伏期、与乙型肝炎相关的评分以及致伤药物的肝毒性信息是RECAM和RUCAM评分不一致的3个主要原因。

结论

RECAM的诊断性能相对优于RUCAM,在中国DILI患者中具有更高的AUC。及时更新LiverTox类别并完善血清标志物以排除乙型肝炎活动,将进一步提高RECAM在草药使用和既往HBV感染解决较为常见地区的适用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/42f0/10932528/33e040514e41/hc9-8-e0235-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验